2 weeks Ago By Defense World Staff
Pyxis Oncology, Inc. ( NASDAQ:PYXS – Get Free Report ) has received a consensus rating of “Buy” from the eight analysts that are presently covering the firm, Marketbeat.com reports.
Eight analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $9.00.
PYXS has been the topic of several recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th.
HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, August 16th. Finally, Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th.
They set a “buy” rating and a $10.00 target price for the company. Check Out Our Latest Stock Analysis on PYXS Pyxis Oncology Stock Down 2.
7 % Pyxis Oncology ( NASDAQ:PYXS – Get Free Report ) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.
33) by $0.04. As a group, sell-side analysts expect that Pyxis Oncology will post -1.
07 EPS for the current fiscal year. Institutional Inflows and Outflows A number of hedge funds and other institutional investors have recently made changes to their positions in PYXS. Fullcircle Wealth LLC acquired a new position in Pyxis Oncology in the second quarter worth $40,000.
SG Americas Securities LLC acquired a new position in shares of Pyxis Oncology during the first quarter valued at $59,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $65,000. Schulhoff & Co.
Inc. boosted its position in shares of Pyxis Oncology by 90.9% in the 2nd quarter.
Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares during the last quarter.
Finally, American Century Companies Inc. boosted its holdings in Pyxis Oncology by 56.0% during the second quarter.
American Century Companies Inc. now owns 58,252 shares of the company’s stock worth $193,000 after buying an additional 20,901 shares during the last quarter. 39.
09% of the stock is owned by institutional investors. Pyxis Oncology Company Profile ( Get Free Report Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Recommended Stories Five stocks we like better than Pyxis Oncology Dividend Capture Strategy: What You Need to Know CarMax’s Impressive Rally: What Investors Should Watch Next How to Choose Top Rated Stocks MarketBeat Week in Review – 9/23 – 9/27 Low PE Growth Stocks: Unlocking Investment Opportunities Wake Up to This Biotech Stock That Still Has Big Potential Upside Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter ..
